Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.
Stephen Eng, PharmD, BCOP
Advertisement
Articles by Stephen Eng, PharmD, BCOP
Treatment selection includes patient factors, cost, adverse effects, and drug interactions.
Treatment often involves a combination of preventive measures, topical therapies, and systemic treatments.
Advertisement
Latest Updated Articles
New Therapy for Chronic Graft-Vs-Host Disease: AxatilimabPublished: February 21st 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Modern Therapies Challenge Radiation’s Role in Early Breast Cancer Survival
3
FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder
4
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
5
